Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 [Accessibility Statement] Skip NavigationGAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register ...

Core Insights - Ozempic, a drug by Novo Nordisk, is widely recognized for treating type 2 diabetes and aiding weight loss, being part of the GLP-1 drug class [1] - Eli Lilly has overtaken Novo Nordisk in the GLP-1 market, capturing 60% of the market share compared to Novo's 39% [4] Group 1: Company Performance - Eli Lilly's drugs, Mounjaro and Zepbound, generated over $11 billion in revenue, showcasing triple-digit growth in the recent quarter [5] - Novo Nordisk's semaglutide is marketed as Ozempic for diabetes and Wegovy for obesity, but its market share has declined as Lilly's products gained popularity [4][6] Group 2: Competitive Advantage - Eli Lilly's success is attributed to effective manufacturing and availability of its products, addressing previous shortages of GLP-1 drugs [6] - A head-to-head study demonstrated that Zepbound led to greater weight loss compared to Wegovy, influencing patient and doctor preferences [6] Group 3: Future Prospects - Novo recently launched a Wegovy pill, while Lilly is under regulatory review for an oral weight loss candidate that offers a hassle-free option without dietary restrictions [7]

Core Insights - Prescription drugs are increasingly expensive, with 27% of Americans reporting they left a prescription unfilled due to high costs [1] Group 1: Impact of High Drug Costs - Nonadherence to medication can worsen chronic conditions, leading to difficult choices between health and essential expenses, which may increase long-term costs [2] - The issue of high drug costs affects both insured and uninsured individuals [2] Group 2: Insurance Coverage and Costs - 20% of Americans have at least one drug not covered by their insurance, leading to financial strain and treatment gaps [3] - On average, 23% of Americans not covered by Medicaid spend over $50 per month out of pocket on prescriptions [3] - The type of insurance plan influences drug costs, with those on health exchange or private plans paying more than those on Medicare, Medicaid, or Tricare [4] Group 3: Payment Structures - The distinction between copay and coinsurance plans affects out-of-pocket expenses, with coinsurance potentially leading to higher costs for expensive drugs [5] - Approximately 8% of Americans are uninsured, limiting their options for medication [5] Group 4: Formulary Tiers - Formulary tiers categorize drugs covered by insurance, impacting out-of-pocket costs, with lower-tier drugs generally having lower copays [6]

Johnson & Johnson (J&J) has chosen Pennsylvania as home to its new $1bn cell therapy manufacturing facility, as the Trump administration looks to onshore drug production to the US amid growing global competition. Once operational, the Montgomery County-based, next-generation production site will create more than 500 skilled biomanufacturing roles. The facility’s development will also open up 4,000 construction positions. The Pennsylvania facility will be J&J’s eleventh site within the state, which is alre ...

Core Insights - Hims & Hers Health is facing challenges in finding new growth drivers after its original sexual-health franchises have matured, particularly following a controversial launch of weight-loss pills that faced backlash from Novo Nordisk and U.S. regulators [1][2] Company Strategy - Hims announced plans to offer a compounded oral semaglutide pill for $49, which is a version of Novo Nordisk's Wegovy, but retreated after warnings from U.S. FDA officials about the legality of such offerings [2] - The company has been positioning itself as an affordable healthcare provider, even investing in high-profile advertising campaigns [5] Financial Performance - Hims had less than $900 million in sales in 2023 but is projected to exceed $2.3 billion in sales by 2025, with expectations of $620 million in fourth-quarter sales, reflecting a 28% increase [6] - The company's sales growth rate has been robust, ranging from 59% to 94% over the past four years, but is forecasted to decline to around 17% over the next two years [7] Market Context - The obesity drug market is projected to reach annual sales of approximately $100 billion by 2030, with a significant portion expected to come from oral medications [8]

长沙晚报掌上长沙2月19日讯（全媒体记者 徐媛）近日，湖南省医保局印发《湖南省城乡居民高血压糖 尿病门诊用药范围及医保支付标准（2026版）》，结合国家医保药品目录（2025年）调整情况，进一步 优化湖南省城乡居民高血压、糖尿病（以下简称"两病"）门诊用药保障政策，建立科学规范的用药范围 和支付标准动态调整机制，切实减轻参保患者用药负担，保障用药需求。 用药范围进一步拓宽，两类核心药品全覆盖 此次政策调整以2025年版"两病"门诊用药范围及支付标准为基础，严格对照《国家基本医疗保险、工伤 保险和生育保险药品目录（2025年）》，将两类关键药品全部纳入"两病"门诊用药范围。 其中，对西药部分、协议期内谈判药品两个部分中高血压用药（药品分类代码XC02抗高血压药、XC03 利尿剂、XC07/XC07Aβ-受体阻滞剂、XC08钙通道阻滞剂、XC09作用于肾素-血管紧张素系统的药 物）、糖尿病用药（药品分类代码XA10），全部纳入两病用药范围，进一步拓宽了参保患者的用药选 择。 动态调整"两病"门诊用药范围，持续优化服务 在医保支付标准方面，湖南省严格按照国家相关规定，对国家谈判及集采范围内的"两病"药品支付标准 进 ...

Group 1 - Nvidia sold its entire stake in a drug-discovery company at the end of last year [1] - ARK Invest is buying the stock of the drug-discovery company [1]

Core Insights - Ipsen S.A. has published its consolidated financial statements for the year 2025, providing a comprehensive overview of its financial performance and strategic direction [1] Financial Performance - The company reported a total revenue of €2.5 billion for 2025, reflecting a growth of 8% compared to the previous year [1] - Net income for the year was recorded at €500 million, which represents a 10% increase year-over-year [1] - The earnings before interest, taxes, depreciation, and amortization (EBITDA) margin improved to 30%, up from 28% in 2024 [1] Strategic Developments - Ipsen has focused on expanding its product portfolio, with significant investments in research and development amounting to €300 million, which is 12% of total revenue [1] - The company has also entered into strategic partnerships aimed at enhancing its market presence in emerging markets [1] Market Outlook - The management has provided guidance for 2026, projecting a revenue growth rate of 7-9%, driven by new product launches and market expansion initiatives [1] - Ipsen anticipates continued strong demand for its key therapeutic areas, particularly in oncology and rare diseases [1]

, the country's first indigenously developed biosimilar of With this launch, the company reinforces its commitment to advancing Currently, more than 100 million people in India are living with diabetes, making it one of the largest diabetic populations globally. "We are committed to making advanced biologics accessible to patients who need them most. ANYRA is a transformative step for affordable retinal care in India. By delivering a high-quality, indigenously developed Aflibercept 2 mg, we are expanding ...

Company Overview - Optimi Health Corp. is a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, specifically focusing on psilocybin and MDMA for mental health therapies [6]. - The company operates two 10,000-square-foot facilities in British Columbia, producing validated MDMA and botanical psilocybin products [6]. Recent Developments - Optimi has announced the export of its GMP-manufactured 5 mg psilocybin capsules to Australia for treating patients with treatment-resistant depression (TRD) under the Authorised Prescriber Scheme [1][2]. - This shipment marks Optimi's second finished drug product supplied to Australia, following the earlier supply of 40 mg and 60 mg MDMA capsules for post-traumatic stress disorder (PTSD) [2]. Product Details - The 5 mg psilocybin capsules are now available to patients in Australia suffering from TRD, with the potential for reimbursement by the Department of Veterans' Affairs (DVA) for eligible patients [3]. - Optimi's psilocybin drug product is manufactured under a Health Canada-issued Drug Establishment Licence, allowing for pharmaceutical-grade production and international export for prescription use [4]. Clinical and Regulatory Framework - Treatment outcomes for patients using psilocybin-assisted therapy in Australia are being tracked through a national patient registry in collaboration with the Australian National University (ANU) [4]. - The company emphasizes its control over the full production lifecycle, including cultivation, extraction, encapsulation, and packaging, ensuring consistency and quality in its products [3].